| NCT03311334 |
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03311334 |
Recruiting |
Boston Biomedical, Inc |
2021-11-30 |
| NCT03029403 |
Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT03029403 |
Recruiting |
University Health Network, Toronto |
2023-02-12 |
| NCT04440943 |
A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT04440943 |
Recruiting |
Celldex Therapeutics |
2022-03-31 |
| NCT04415944 |
Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy |
https://ClinicalTrials.gov/show/NCT04415944 |
Recruiting |
Wake Forest University Health Sciences |
2021-01-31 |
| NCT04019288 |
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT04019288 |
Recruiting |
M.D. Anderson Cancer Center |
2020-09-30 |
| NCT03657043 |
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) |
https://ClinicalTrials.gov/show/NCT03657043 |
Recruiting |
Seattle Genetics, Inc. |
2022-08-31 |
| NCT03393884 |
Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) |
https://ClinicalTrials.gov/show/NCT03393884 |
Active, not recruiting |
Celsion |
2022-02-28 |
| NCT03378128 |
Debulking Surgery in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03378128 |
Recruiting |
Case Comprehensive Cancer Center |
2020-08-31 |
| NCT03373058 |
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery |
https://ClinicalTrials.gov/show/NCT03373058 |
Recruiting |
Affiliated Cancer Hospital & Institute of Guangzhou Medical University |
2021-07-01 |
| NCT03824704 |
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) |
https://ClinicalTrials.gov/show/NCT03824704 |
Active, not recruiting |
Clovis Oncology, Inc. |
2021-01-31 |
| NCT03363867 |
BEACON - ABC in Recurrent Platinum Resistant HGSOC |
https://ClinicalTrials.gov/show/NCT03363867 |
Recruiting |
Peter MacCallum Cancer Centre, Australia |
2022-07-01 |
| NCT03326193 |
Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT03326193 |
Active, not recruiting |
Tesaro, Inc. |
2020-12-24 |
| NCT03321188 |
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT03321188 |
Recruiting |
University of Kansas Medical Center |
2020-12-15 |
| NCT03283943 |
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. |
https://ClinicalTrials.gov/show/NCT03283943 |
Recruiting |
British Columbia Cancer Agency |
2020-12-16 |
| NCT03213964 |
Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int |
https://ClinicalTrials.gov/show/NCT03213964 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2025-01-01 |
| NCT03188432 |
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03188432 |
Recruiting |
Wake Forest University Health Sciences |
2020-11-01 |
| NCT03188159 |
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03188159 |
Recruiting |
National University Hospital, Singapore |
2021-07-01 |
| NCT03150121 |
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage |
https://ClinicalTrials.gov/show/NCT03150121 |
Recruiting |
Sheba Medical Center |
2022-12-31 |
| NCT03126812 |
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03126812 |
Recruiting |
The Netherlands Cancer Institute |
2020-06-30 |
| NCT03113487 |
P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT03113487 |
Recruiting |
City of Hope Medical Center |
2021-01-06 |
| NCT03056833 |
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03056833 |
Recruiting |
University of Pittsburgh |
2020-06-01 |
| NCT03054909 |
IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03054909 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2020-12-31 |
| NCT03054298 |
CAR T Cells in Mesothelin Expressing Cancers |
https://ClinicalTrials.gov/show/NCT03054298 |
Recruiting |
University of Pennsylvania |
2021-03-31 |
| NCT03030287 |
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT03030287 |
Completed |
OncoMed Pharmaceuticals, Inc. |
2020-04-30 |
| NCT03026062 |
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT03026062 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-31 |
| NCT02948426 |
Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02948426 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-04-01 |
| NCT02915523 |
Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02915523 |
Active, not recruiting |
Syndax Pharmaceuticals |
2019-07-31 |
| NCT02903771 |
Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. |
https://ClinicalTrials.gov/show/NCT02903771 |
Completed |
Kazia Therapeutics Limited |
2020-03-24 |
| NCT02884648 |
Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery |
https://ClinicalTrials.gov/show/NCT02884648 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT02873962 |
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib |
https://ClinicalTrials.gov/show/NCT02873962 |
Recruiting |
Dana-Farber Cancer Institute |
2020-08-31 |
| NCT02865811 |
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02865811 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2021-02-28 |
| NCT02859038 |
Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) |
https://ClinicalTrials.gov/show/NCT02859038 |
Recruiting |
Shanghai Gynecologic Oncology Group |
2022-12-31 |
| NCT02853318 |
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02853318 |
Active, not recruiting |
Roswell Park Cancer Institute |
2020-08-03 |
| NCT02786524 |
Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy |
https://ClinicalTrials.gov/show/NCT02786524 |
Completed |
University of Michigan |
2017-10-31 |
| NCT02785250 |
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02785250 |
Active, not recruiting |
ImmunoVaccine Technologies, Inc. (IMV Inc.) |
2020-02-29 |
| NCT02759588 |
GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02759588 |
Recruiting |
Genelux Corporation |
2020-07-31 |
| NCT02728830 |
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers |
https://ClinicalTrials.gov/show/NCT02728830 |
Active, not recruiting |
Duke University |
2019-01-31 |
| NCT02728622 |
Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane |
https://ClinicalTrials.gov/show/NCT02728622 |
Completed |
Nordic Society of Gynaecological Oncology - Clinical Trials Unit |
2008-01-31 |
| NCT02726997 |
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) |
https://ClinicalTrials.gov/show/NCT02726997 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-07-30 |
| NCT02725489 |
Pilot Study of Durvalumab and Vigil in Advanced Women’s Cancers |
https://ClinicalTrials.gov/show/NCT02725489 |
Active, not recruiting |
Mary Crowley Medical Research Center |
2019-12-30 |
| NCT02713386 |
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02713386 |
Active, not recruiting |
NRG Oncology |
2020-09-30 |
| NCT02659241 |
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02659241 |
Recruiting |
M.D. Anderson Cancer Center |
2021-12-31 |
| NCT02658214 |
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02658214 |
Completed |
AstraZeneca |
2019-11-14 |
| NCT02657889 |
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02657889 |
Active, not recruiting |
Tesaro, Inc. |
2018-05-31 |
| NCT02631876 |
A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02631876 |
Completed |
ImmunoGen, Inc. |
2019-01-31 |
| NCT02627443 |
Carboplatin, Gemcitabine Hydrochloride, and ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02627443 |
Recruiting |
National Cancer Institute (NCI) |
2020-11-30 |
| NCT02606305 |
Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02606305 |
Active, not recruiting |
ImmunoGen, Inc. |
2021-01-31 |
| NCT02595892 |
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02595892 |
Active, not recruiting |
National Cancer Institute (NCI) |
2021-03-19 |
| NCT02650986 |
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 |
https://ClinicalTrials.gov/show/NCT02650986 |
Recruiting |
Roswell Park Cancer Institute |
2021-06-20 |
| NCT01749397 |
Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01749397 |
Completed |
National Cancer Institute (NCI) |
2017-10-20 |
| NCT03038100 |
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03038100 |
Active, not recruiting |
Hoffmann-La Roche |
2020-03-30 |
| NCT02571725 |
PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02571725 |
Recruiting |
New Mexico Cancer Care Alliance |
2020-02-29 |
| NCT01970722 |
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01970722 |
Recruiting |
City of Hope Medical Center |
2021-05-19 |
| NCT02520154 |
Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02520154 |
Recruiting |
M.D. Anderson Cancer Center |
2020-07-31 |
| NCT02498600 |
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02498600 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-09-05 |
| NCT02489006 |
A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02489006 |
Recruiting |
University Health Network, Toronto |
2021-06-30 |
| NCT02480374 |
Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02480374 |
Active, not recruiting |
Celsion |
2017-06-30 |
| NCT02470299 |
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT02470299 |
Completed |
New Mexico Cancer Care Alliance |
2018-10-08 |
| NCT02444195 |
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients |
https://ClinicalTrials.gov/show/NCT02444195 |
Completed |
University of Michigan |
2016-05-01 |
| NCT02433626 |
Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies |
https://ClinicalTrials.gov/show/NCT02433626 |
Recruiting |
Critical Outcome Technologies Inc. |
2019-12-31 |
| NCT02364713 |
MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02364713 |
Recruiting |
Mayo Clinic |
2027-03-17 |
| NCT02349958 |
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy |
https://ClinicalTrials.gov/show/NCT02349958 |
Recruiting |
Bay Area Gynecology Oncology |
2022-01-31 |
| NCT02324439 |
Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission |
https://ClinicalTrials.gov/show/NCT02324439 |
Recruiting |
Southern Illinois University |
2021-07-31 |
| NCT02316834 |
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02316834 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-02-01 |
| NCT02312245 |
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02312245 |
Recruiting |
Mayo Clinic |
2020-06-30 |
| NCT02311907 |
Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02311907 |
Completed |
Alliance for Clinical Trials in Oncology |
2012-08-31 |
| NCT02262455 |
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02262455 |
Completed |
Santa Maria Biotherapeutics |
2017-01-13 |
| NCT02142803 |
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02142803 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-06-30 |
| NCT02125513 |
Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT02125513 |
Recruiting |
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
2020-08-31 |
| NCT02124421 |
HOT: HIPEC in Ovarian Cancer as Initial Treatment |
https://ClinicalTrials.gov/show/NCT02124421 |
Recruiting |
Mercy Medical Center |
2020-04-30 |
| NCT02122185 |
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02122185 |
Recruiting |
University of Chicago |
2021-02-25 |
| NCT02121990 |
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02121990 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT02111941 |
Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy |
https://ClinicalTrials.gov/show/NCT02111941 |
Active, not recruiting |
Mayo Clinic |
2017-08-18 |
| NCT02101775 |
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT02101775 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-12-01 |
| NCT01314105 |
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01314105 |
Completed |
Boehringer Ingelheim |
2013-07-31 |
| NCT01313078 |
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01313078 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-09-30 |
| NCT01312389 |
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01312389 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2012-05-31 |
| NCT01308944 |
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT01308944 |
Completed |
Washington University School of Medicine |
2014-08-31 |
| NCT01306032 |
Phase II ABT-888 With Cyclophosphamide |
https://ClinicalTrials.gov/show/NCT01306032 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-12-31 |
| NCT01281514 |
A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer |
https://ClinicalTrials.gov/show/NCT01281514 |
Completed |
Fox Chase Cancer Center |
2018-01-08 |
| NCT02046421 |
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02046421 |
Completed |
University of Chicago |
2018-05-31 |
| NCT02042430 |
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT02042430 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-03-31 |
| NCT03093155 |
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab |
https://ClinicalTrials.gov/show/NCT03093155 |
Active, not recruiting |
Yale University |
2021-02-28 |
| NCT02020707 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers |
https://ClinicalTrials.gov/show/NCT02020707 |
Recruiting |
Mayo Clinic |
2020-10-03 |
| NCT04296890 |
A Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
https://ClinicalTrials.gov/show/NCT04296890 |
Recruiting |
ImmunoGen, Inc. |
2021-07-31 |
| NCT03355976 |
BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas |
https://ClinicalTrials.gov/show/NCT03355976 |
Recruiting |
Brown University |
2020-02-29 |
| NCT03329950 |
A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03329950 |
Recruiting |
Celldex Therapeutics |
2021-08-31 |
| NCT01974765 |
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies |
https://ClinicalTrials.gov/show/NCT01974765 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-10-31 |
| NCT01968213 |
A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01968213 |
Active, not recruiting |
Clovis Oncology, Inc. |
2017-04-30 |
| NCT01940172 |
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01940172 |
Completed |
TetraLogic Pharmaceuticals |
2015-09-30 |
| NCT01905163 |
Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients |
https://ClinicalTrials.gov/show/NCT01905163 |
Completed |
Centre Jean Perrin |
2016-08-31 |
| NCT01891344 |
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) |
https://ClinicalTrials.gov/show/NCT01891344 |
Active, not recruiting |
Clovis Oncology, Inc. |
2019-11-05 |
| NCT01849874 |
A Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01849874 |
Active, not recruiting |
Pfizer |
2016-04-01 |
| NCT01846611 |
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01846611 |
Completed |
Janssen Research & Development, LLC |
2018-01-18 |
| NCT01767675 |
Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01767675 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT01764802 |
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01764802 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-06-01 |
| NCT01764789 |
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01764789 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-01-31 |
| NCT01747798 |
Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01747798 |
Completed |
Mayo Clinic |
2014-01-10 |
| NCT01704651 |
Accelerating Gastrointestinal Recovery |
https://ClinicalTrials.gov/show/NCT01704651 |
Completed |
Mayo Clinic |
2015-08-31 |
| NCT01670799 |
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01670799 |
Completed |
New Mexico Cancer Care Alliance |
2015-12-31 |
| NCT01669798 |
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01669798 |
Completed |
Duke University |
2017-09-10 |
| NCT01669226 |
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01669226 |
Completed |
Shanghai Gynecologic Oncology Group |
2015-09-30 |
| NCT01666444 |
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01666444 |
Completed |
Celgene |
2016-07-31 |
| NCT01663857 |
A Study LY2228820 for Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01663857 |
Completed |
Eli Lilly and Company |
2017-05-25 |
| NCT01652794 |
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer |
https://ClinicalTrials.gov/show/NCT01652794 |
Completed |
Case Comprehensive Cancer Center |
2014-05-31 |
| NCT01652079 |
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01652079 |
Completed |
Massachusetts General Hospital |
2018-03-31 |
| NCT01649336 |
A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01649336 |
Completed |
Array BioPharma |
2016-03-31 |
| NCT01626014 |
Interactive Educational Website for Women With Ovarian Cancer & Caregivers |
https://ClinicalTrials.gov/show/NCT01626014 |
Completed |
University of Minnesota |
2014-12-31 |
| NCT01610869 |
Low Dose Cyclophosphamide +/– Nintedanib in Advanced Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01610869 |
Completed |
University College, London |
2018-01-11 |
| NCT01610206 |
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01610206 |
Active, not recruiting |
University of Virginia |
2018-06-01 |
| NCT01606241 |
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01606241 |
Completed |
Mayo Clinic |
2014-09-25 |
| NCT01556841 |
The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01556841 |
Completed |
University College, London |
2019-04-19 |
| NCT01536054 |
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT01536054 |
Completed |
Roswell Park Cancer Institute |
2015-04-21 |
| NCT01506856 |
Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial |
https://ClinicalTrials.gov/show/NCT01506856 |
Active, not recruiting |
Gynecologic Oncology Trial & Investigation Consortium |
2019-11-30 |
| NCT01504126 |
Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01504126 |
Completed |
M.D. Anderson Cancer Center |
2019-08-15 |
| NCT01482715 |
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) |
https://ClinicalTrials.gov/show/NCT01482715 |
Completed |
Clovis Oncology, Inc. |
2019-03-31 |
| NCT01478685 |
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01478685 |
Completed |
Celgene |
2015-11-17 |
| NCT01462890 |
Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01462890 |
Active, not recruiting |
AGO Study Group |
2018-11-30 |
| NCT01459380 |
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01459380 |
Completed |
National Cancer Institute (NCI) |
2016-06-08 |
| NCT01447706 |
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers |
https://ClinicalTrials.gov/show/NCT01447706 |
Completed |
Merrimack Pharmaceuticals |
2013-09-30 |
| NCT01442051 |
Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01442051 |
Completed |
Memorial Sloan Kettering Cancer Center |
2019-07-01 |
| NCT01416038 |
Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01416038 |
Completed |
ImmunoVaccine Technologies, Inc. (IMV Inc.) |
2013-05-31 |
| NCT01402271 |
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01402271 |
Active, not recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2019-05-15 |
| NCT01391351 |
Search for Predictors of Therapeutic Response in Ovarian Carcinoma |
https://ClinicalTrials.gov/show/NCT01391351 |
Completed |
Centre Francois Baclesse |
2015-11-30 |
| NCT04209855 |
A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
https://ClinicalTrials.gov/show/NCT04209855 |
Recruiting |
ImmunoGen, Inc. |
2022-06-30 |
| NCT04267575 |
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites |
https://ClinicalTrials.gov/show/NCT04267575 |
Recruiting |
Jerome Canady Research Institute for Advanced Biological & Technological Sciences |
2020-07-30 |
| NCT04213794 |
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study |
https://ClinicalTrials.gov/show/NCT04213794 |
Recruiting |
Mayo Clinic |
2025-01-30 |
| NCT04158336 |
A Study of ZN-c3 in Participants With Solid Tumors |
https://ClinicalTrials.gov/show/NCT04158336 |
Recruiting |
K-Group Beta |
2023-05-31 |
| NCT04034927 |
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT04034927 |
Recruiting |
National Cancer Institute (NCI) |
2022-12-31 |
| NCT04029909 |
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT04029909 |
Recruiting |
Lee’s Pharmaceutical Limited |
2019-12-31 |
| NCT04025216 |
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers |
https://ClinicalTrials.gov/show/NCT04025216 |
Recruiting |
Tmunity Therapeutics |
2022-12-31 |
| NCT04001023 |
Overcoming Chemoresistance in Advanced Ovarian Cancer Via Targeting Hypoxia |
https://ClinicalTrials.gov/show/NCT04001023 |
Recruiting |
Turku University Hospital |
2022-12-31 |
| NCT03983226 |
Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) |
https://ClinicalTrials.gov/show/NCT03983226 |
Recruiting |
Shanghai Gynecologic Oncology Group |
2023-06-30 |
| NCT03976999 |
Development of a Cinical and Biological Database in Ovarian, Fallopian Tube and Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT03976999 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2020-07-31 |
| NCT03968406 |
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers |
https://ClinicalTrials.gov/show/NCT03968406 |
Recruiting |
M.D. Anderson Cancer Center |
2021-10-11 |
| NCT03943173 |
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery |
https://ClinicalTrials.gov/show/NCT03943173 |
Recruiting |
M.D. Anderson Cancer Center |
2021-03-03 |
| NCT03922776 |
Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03922776 |
Recruiting |
Centre Oscar Lambret |
2019-09-30 |
| NCT03907527 |
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03907527 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2022-04-01 |
| NCT03849469 |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03849469 |
Recruiting |
Xencor, Inc. |
2026-09-30 |
| NCT03839524 |
A Trial Evaluating TG4050 in Ovarian Carcinoma. |
https://ClinicalTrials.gov/show/NCT03839524 |
Recruiting |
Transgene |
2021-12-31 |
| NCT03783949 |
European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03783949 |
Active, not recruiting |
Universitaire Ziekenhuizen Leuven |
2021-03-31 |
| NCT03771651 |
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube |
https://ClinicalTrials.gov/show/NCT03771651 |
Recruiting |
University of Oklahoma |
2021-03-01 |
| NCT03759587 |
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03759587 |
Active, not recruiting |
Takeda |
2019-03-17 |
| NCT03748186 |
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers |
https://ClinicalTrials.gov/show/NCT03748186 |
Recruiting |
Sutro Biopharma, Inc. |
2022-08-31 |
| NCT03693248 |
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03693248 |
Recruiting |
Seoul National University Hospital |
2023-12-31 |
| NCT03691376 |
Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03691376 |
Recruiting |
Roswell Park Cancer Institute |
2020-10-01 |
| NCT03648489 |
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) |
https://ClinicalTrials.gov/show/NCT03648489 |
Recruiting |
Imperial College London |
2022-03-31 |
| NCT03635489 |
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03635489 |
Active, not recruiting |
Hoffmann-La Roche |
2020-12-29 |
| NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
https://ClinicalTrials.gov/show/NCT03604315 |
Recruiting |
M.D. Anderson Cancer Center |
2022-12-31 |
| NCT03586661 |
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT03586661 |
Recruiting |
M.D. Anderson Cancer Center |
2021-04-30 |
| NCT03585764 |
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03585764 |
Recruiting |
University of Pennsylvania |
2020-10-31 |
| NCT03564340 |
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03564340 |
Recruiting |
Regeneron Pharmaceuticals |
2022-05-11 |
| NCT03540017 |
HIPEC After Initial CRS in Patients Who Have Received NACT |
https://ClinicalTrials.gov/show/NCT03540017 |
Recruiting |
Northwell Health |
2020-07-05 |
| NCT03522246 |
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT03522246 |
Recruiting |
Clovis Oncology, Inc. |
2024-12-30 |
| NCT03519178 |
A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy |
https://ClinicalTrials.gov/show/NCT03519178 |
Recruiting |
Pfizer |
2023-03-19 |
| NCT03508570 |
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis |
https://ClinicalTrials.gov/show/NCT03508570 |
Recruiting |
M.D. Anderson Cancer Center |
2021-01-01 |
| NCT03462212 |
Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer. |
https://ClinicalTrials.gov/show/NCT03462212 |
Recruiting |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2018-11-01 |
| NCT03430700 |
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT03430700 |
Recruiting |
University College, London |
2020-11-16 |
| NCT01262040 |
Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive |
https://ClinicalTrials.gov/show/NCT01262040 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-10-29 |
| NCT01253681 |
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01253681 |
Completed |
Amgen |
2012-10-31 |
| NCT01248962 |
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01248962 |
Completed |
Memorial Sloan Kettering Cancer Center |
2018-08-31 |
| NCT01237067 |
Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers |
https://ClinicalTrials.gov/show/NCT01237067 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-11-16 |
| NCT01223235 |
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab |
https://ClinicalTrials.gov/show/NCT01223235 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-09-30 |
| NCT01220154 |
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01220154 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2021-03-31 |
| NCT01219777 |
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel for Primary Ovarian |
https://ClinicalTrials.gov/show/NCT01219777 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01209195 |
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers |
https://ClinicalTrials.gov/show/NCT01209195 |
Completed |
Merrimack Pharmaceuticals |
2014-05-31 |
| NCT01204749 |
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01204749 |
Completed |
Amgen |
2013-03-31 |
| NCT01196741 |
Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01196741 |
Completed |
University College, London |
2012-11-30 |
| NCT01196559 |
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01196559 |
Completed |
The Catholic University of Korea |
2014-10-31 |
| NCT01188876 |
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01188876 |
Completed |
Massachusetts General Hospital |
2016-07-31 |
| NCT01175343 |
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01175343 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT01170299 |
Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer |
https://ClinicalTrials.gov/show/NCT01170299 |
Completed |
National Cancer Institute (NCI) |
2012-12-31 |
| NCT01167712 |
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01167712 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-12-01 |
| NCT01166737 |
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01166737 |
Active, not recruiting |
AGO Study Group |
2019-12-31 |
| NCT01105650 |
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01105650 |
Completed |
Masonic Cancer Center, University of Minnesota |
2014-04-30 |
| NCT01097746 |
First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01097746 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT01091428 |
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer |
https://ClinicalTrials.gov/show/NCT01091428 |
Completed |
Takeda |
2014-08-12 |
| NCT01091259 |
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT01091259 |
Completed |
NYU Langone Health |
2014-02-28 |
| NCT01081262 |
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01081262 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-02-25 |
| NCT01079832 |
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies |
https://ClinicalTrials.gov/show/NCT01079832 |
Completed |
Case Comprehensive Cancer Center |
2012-05-31 |
| NCT01074411 |
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01074411 |
Completed |
National Cancer Institute (NCI) |
2014-04-04 |
| NCT01065662 |
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies |
https://ClinicalTrials.gov/show/NCT01065662 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2013-09-30 |
| NCT01031381 |
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01031381 |
Completed |
University of Pittsburgh |
2014-01-31 |
| NCT01010126 |
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer |
https://ClinicalTrials.gov/show/NCT01010126 |
Completed |
National Cancer Institute (NCI) |
2017-03-13 |
| NCT01001910 |
Pemetrexed Disodium and Carboplatin in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT01001910 |
Completed |
Albert Einstein College of Medicine |
2015-01-31 |
| NCT00993655 |
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00993655 |
Completed |
Canadian Cancer Trials Group |
2016-03-10 |
| NCT00993616 |
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin |
https://ClinicalTrials.gov/show/NCT00993616 |
Completed |
National Cancer Institute (NCI) |
2012-07-31 |
| NCT00989651 |
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00989651 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-09-01 |
| NCT00989131 |
Study of Paclitaxel in Patients With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00989131 |
Completed |
Oasmia Pharmaceutical AB |
2013-10-31 |
| NCT00959582 |
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) |
https://ClinicalTrials.gov/show/NCT00959582 |
Completed |
Merck Sharp & Dohme Corp. |
2011-10-31 |
| NCT00954174 |
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00954174 |
Active, not recruiting |
Gynecologic Oncology Group |
2019-03-30 |
| NCT00951496 |
Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00951496 |
Active, not recruiting |
National Cancer Institute (NCI) |
2016-01-11 |
| NCT00880360 |
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00880360 |
Completed |
The University of Texas Health Science Center at San Antonio |
2010-04-30 |
| NCT00872989 |
S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00872989 |
Completed |
Southwest Oncology Group |
2013-10-31 |
| NCT00857545 |
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission |
https://ClinicalTrials.gov/show/NCT00857545 |
Completed |
Gynecologic Oncology Group |
2015-09-30 |
| NCT00856180 |
Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies |
https://ClinicalTrials.gov/show/NCT00856180 |
Completed |
Dana-Farber Cancer Institute |
2010-04-30 |
| NCT00850772 |
Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00850772 |
Completed |
Queensland Centre for Gynaecological Cancer |
2013-08-31 |
| NCT00842452 |
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00842452 |
Completed |
Case Comprehensive Cancer Center |
2011-04-30 |
| NCT01673217 |
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01673217 |
Completed |
Roswell Park Cancer Institute |
2011-10-31 |
| NCT03924245 |
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers |
https://ClinicalTrials.gov/show/NCT03924245 |
Recruiting |
Vanderbilt-Ingram Cancer Center |
2023-09-30 |
| NCT03759600 |
Japan Phase 2 Study of Niraparib in Patients With Advanced, Relapsed Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT03759600 |
Active, not recruiting |
Takeda |
2019-07-01 |
| NCT01853644 |
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT01853644 |
Active, not recruiting |
Northwestern University |
2018-10-02 |
| NCT00801320 |
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00801320 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-08-31 |
| NCT03740165 |
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43) |
https://ClinicalTrials.gov/show/NCT03740165 |
Recruiting |
Merck Sharp & Dohme Corp. |
2025-08-08 |
| NCT00803569 |
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT00803569 |
Completed |
Ludwig Institute for Cancer Research |
2011-01-24 |
| NCT00770536 |
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR |
https://ClinicalTrials.gov/show/NCT00770536 |
Completed |
Amgen |
2012-01-31 |
| NCT00768144 |
Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma |
https://ClinicalTrials.gov/show/NCT00768144 |
Completed |
Dana-Farber Cancer Institute |
2012-05-31 |
| NCT00721162 |
Study of Ramucirumab in Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00721162 |
Completed |
Eli Lilly and Company |
2012-05-31 |
| NCT00719303 |
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00719303 |
Recruiting |
Gynecologic Oncology Group |
2020-12-31 |
| NCT00702299 |
Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00702299 |
Completed |
University of Arizona |
2012-01-31 |
| NCT00698451 |
A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers |
https://ClinicalTrials.gov/show/NCT00698451 |
Completed |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2010-10-31 |
| NCT00692900 |
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00692900 |
Completed |
University of Pittsburgh |
2013-06-30 |
| NCT00672295 |
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer |
https://ClinicalTrials.gov/show/NCT00672295 |
Completed |
Duke University |
2011-09-30 |
| NCT00652119 |
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin |
https://ClinicalTrials.gov/show/NCT00652119 |
Active, not recruiting |
Massachusetts General Hospital |
2009-08-31 |
| NCT00617773 |
Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00617773 |
Completed |
Recepta Biopharma |
2012-06-30 |
| NCT00616941 |
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00616941 |
Completed |
Ludwig Institute for Cancer Research |
2011-06-30 |
| NCT00602277 |
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy |
https://ClinicalTrials.gov/show/NCT00602277 |
Completed |
National Cancer Institute (NCI) |
2016-08-31 |
| NCT00588237 |
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00588237 |
Completed |
Memorial Sloan Kettering Cancer Center |
2014-11-30 |
| NCT00569673 |
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00569673 |
Completed |
Gynecologic Oncology Group |
2012-01-31 |
| NCT00565851 |
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00565851 |
Active, not recruiting |
National Cancer Institute (NCI) |
2019-11-14 |
| NCT00562640 |
Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) |
https://ClinicalTrials.gov/show/NCT00562640 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT00550784 |
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00550784 |
Completed |
City of Hope Medical Center |
2014-10-31 |
| NCT00543049 |
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor |
https://ClinicalTrials.gov/show/NCT00543049 |
Completed |
AGO Study Group |
2012-06-30 |
| NCT00538031 |
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00538031 |
Active, not recruiting |
City of Hope Medical Center |
2020-12-31 |
| NCT00526617 |
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients |
https://ClinicalTrials.gov/show/NCT00526617 |
Completed |
AbbVie |
2010-06-30 |
| NCT00520013 |
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors |
https://ClinicalTrials.gov/show/NCT00520013 |
Completed |
Dana-Farber Cancer Institute |
2010-10-31 |
| NCT00517621 |
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire |
https://ClinicalTrials.gov/show/NCT00517621 |
Completed |
ARCAGY/ GINECO GROUP |
2010-09-30 |
| NCT00515372 |
Depression Treatment and Screening in Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT00515372 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT00504257 |
Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma |
https://ClinicalTrials.gov/show/NCT00504257 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2012-10-31 |
| NCT00501644 |
Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00501644 |
Completed |
M.D. Anderson Cancer Center |
2009-01-31 |
| NCT00483782 |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00483782 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00479817 |
Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00479817 |
Completed |
Amgen |
2009-08-11 |
| NCT00478452 |
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT00478452 |
Completed |
University of Pennsylvania |
2008-08-31 |
| NCT00466986 |
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00466986 |
Completed |
Southeastern Gynecologic Oncology |
2011-10-31 |
| NCT00466960 |
Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy |
https://ClinicalTrials.gov/show/NCT00466960 |
Completed |
University of Washington |
2011-07-31 |
| NCT00459290 |
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00459290 |
Completed |
Gynecologic Oncology Group |
2010-07-31 |
| NCT00443196 |
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
https://ClinicalTrials.gov/show/NCT00443196 |
Completed |
Pierian Biosciences |
NA |
| NCT00436501 |
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00436501 |
Completed |
National Cancer Institute (NCI) |
2011-03-31 |
| NCT00436215 |
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00436215 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-06-26 |
| NCT00429793 |
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00429793 |
Completed |
National Cancer Institute (NCI) |
2012-01-31 |
| NCT00428610 |
A Study of Chemotherapy Treatment for Patients With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00428610 |
Completed |
Eli Lilly and Company |
2011-02-28 |
| NCT00421889 |
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment |
https://ClinicalTrials.gov/show/NCT00421889 |
Completed |
Onxeo |
2009-02-28 |
| NCT00391118 |
Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (“Sugar Pill”) |
https://ClinicalTrials.gov/show/NCT00391118 |
Completed |
Eli Lilly and Company |
2010-04-30 |
| NCT00390234 |
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma |
https://ClinicalTrials.gov/show/NCT00390234 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT00388037 |
Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00388037 |
Completed |
National Cancer Institute (NCI) |
2012-01-31 |
| NCT00382811 |
OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00382811 |
Completed |
MEI Pharma, Inc. |
2009-04-30 |
| NCT00381888 |
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer |
https://ClinicalTrials.gov/show/NCT00381888 |
Completed |
Masonic Cancer Center, University of Minnesota |
2009-01-31 |
| NCT00357448 |
Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00357448 |
Completed |
University of Washington |
2009-11-30 |
| NCT00343044 |
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers |
https://ClinicalTrials.gov/show/NCT00343044 |
Completed |
Benaroya Research Institute |
2010-01-31 |
| NCT00334893 |
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00334893 |
Completed |
National Cancer Institute (NCI) |
2012-03-31 |
| NCT00318370 |
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy |
https://ClinicalTrials.gov/show/NCT00318370 |
Completed |
Morphotek |
2010-02-28 |
| NCT00317772 |
Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00317772 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-09-04 |
| NCT00293293 |
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine |
https://ClinicalTrials.gov/show/NCT00293293 |
Completed |
Masonic Cancer Center, University of Minnesota |
2009-04-30 |
| NCT00799110 |
Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod |
https://ClinicalTrials.gov/show/NCT00799110 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT00287885 |
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer |
https://ClinicalTrials.gov/show/NCT00287885 |
Completed |
Masonic Cancer Center, University of Minnesota |
2008-12-31 |
| NCT00281632 |
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00281632 |
Completed |
GlaxoSmithKline |
2008-04-30 |
| NCT00278343 |
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00278343 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00275028 |
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00275028 |
Completed |
National Cancer Institute (NCI) |
2010-03-31 |
| NCT00268918 |
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients |
https://ClinicalTrials.gov/show/NCT00268918 |
Completed |
Dana-Farber Cancer Institute |
2007-01-31 |
| NCT00267696 |
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00267696 |
Completed |
Ohio State University Comprehensive Cancer Center |
2013-09-30 |
| NCT02855944 |
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients |
https://ClinicalTrials.gov/show/NCT02855944 |
Recruiting |
Clovis Oncology, Inc. |
2022-06-30 |
| NCT00263822 |
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00263822 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2008-02-29 |
| NCT00262990 |
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00262990 |
Completed |
Novartis |
2010-02-28 |
| NCT00262847 |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00262847 |
Completed |
National Cancer Institute (NCI) |
2010-11-30 |
| NCT00245050 |
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer |
https://ClinicalTrials.gov/show/NCT00245050 |
Completed |
Case Comprehensive Cancer Center |
2008-04-30 |
| NCT00230542 |
Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00230542 |
Completed |
Dana-Farber Cancer Institute |
2007-07-31 |
| NCT00226915 |
Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma |
https://ClinicalTrials.gov/show/NCT00226915 |
Completed |
Japanese Gynecologic Oncology Group |
2012-06-30 |
| NCT00217555 |
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00217555 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-02-28 |
| NCT00217529 |
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00217529 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-11-30 |
| NCT00191646 |
An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy |
https://ClinicalTrials.gov/show/NCT00191646 |
Completed |
Eli Lilly and Company |
2009-08-31 |
| NCT00191607 |
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. |
https://ClinicalTrials.gov/show/NCT00191607 |
Completed |
Eli Lilly and Company |
NA |
| NCT00189566 |
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse |
https://ClinicalTrials.gov/show/NCT00189566 |
Completed |
ARCAGY/ GINECO GROUP |
NA |
| NCT00189553 |
Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse |
https://ClinicalTrials.gov/show/NCT00189553 |
Completed |
ARCAGY/ GINECO GROUP |
2009-01-31 |
| NCT00189358 |
A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy |
https://ClinicalTrials.gov/show/NCT00189358 |
Completed |
AGO Study Group |
NA |
| NCT00189345 |
Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients |
https://ClinicalTrials.gov/show/NCT00189345 |
Completed |
AGO Study Group |
NA |
| NCT00182767 |
Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00182767 |
Completed |
National Cancer Institute (NCI) |
2012-04-30 |
| NCT00157573 |
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00157573 |
Completed |
Massachusetts General Hospital |
2008-10-31 |
| NCT00157560 |
Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma |
https://ClinicalTrials.gov/show/NCT00157560 |
Completed |
Massachusetts General Hospital |
2006-11-30 |
| NCT00138242 |
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00138242 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00114166 |
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00114166 |
Completed |
Gynecologic Oncology Group |
2011-01-31 |
| NCT00112957 |
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00112957 |
Completed |
Ludwig Institute for Cancer Research |
2009-05-31 |
| NCT00112086 |
OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206 |
https://ClinicalTrials.gov/show/NCT00112086 |
Completed |
Japan Clinical Oncology Group |
2007-02-28 |
| NCT00108745 |
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00108745 |
Active, not recruiting |
Gynecologic Oncology Group |
2022-01-01 |
| NCT00103545 |
Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response |
https://ClinicalTrials.gov/show/NCT00103545 |
Completed |
AGO Study Group |
NA |
| NCT00098878 |
Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00098878 |
Completed |
National Cancer Institute (NCI) |
2010-07-31 |
| NCT00096993 |
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00096993 |
Completed |
Genentech, Inc. |
2007-09-30 |
| NCT00096239 |
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00096239 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00096200 |
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00096200 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00091377 |
Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00091377 |
Completed |
MEI Pharma, Inc. |
2007-12-31 |
| NCT00002960 |
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) |
https://ClinicalTrials.gov/show/NCT00002960 |
Completed |
Merck Sharp & Dohme Corp. |
2000-07-31 |
| NCT00003358 |
Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00003358 |
Completed |
Memorial Sloan Kettering Cancer Center |
2001-01-31 |
| NCT00004060 |
Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00004060 |
Completed |
Daiichi Sankyo, Inc. |
2000-09-30 |
| NCT00006041 |
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00006041 |
Completed |
Memorial Sloan Kettering Cancer Center |
2002-02-28 |
| NCT00006235 |
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00006235 |
Completed |
Gynecologic Oncology Group |
2006-02-28 |
| NCT00085358 |
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) |
https://ClinicalTrials.gov/show/NCT00085358 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00002538 |
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers |
https://ClinicalTrials.gov/show/NCT00002538 |
Completed |
Gynecologic Oncology Group |
2010-03-31 |
| NCT00004012 |
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00004012 |
Completed |
Memorial Sloan Kettering Cancer Center |
2000-12-31 |
| NCT00003944 |
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00003944 |
Completed |
Fox Chase Cancer Center |
1999-12-31 |
| NCT00019552 |
Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00019552 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00004082 |
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors |
https://ClinicalTrials.gov/show/NCT00004082 |
Completed |
National Cancer Institute (NCI) |
2003-09-30 |
| NCT00002600 |
Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer |
https://ClinicalTrials.gov/show/NCT00002600 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2001-07-25 |
| NCT00003967 |
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00003967 |
Completed |
Gynecologic Oncology Group |
2006-04-30 |
| NCT00003345 |
Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00003345 |
Completed |
Memorial Sloan Kettering Cancer Center |
2001-10-31 |
| NCT00079430 |
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00079430 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00014690 |
ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00014690 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00010179 |
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer |
https://ClinicalTrials.gov/show/NCT00010179 |
Completed |
Canadian Cancer Trials Group |
2002-10-22 |
| NCT00003120 |
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission |
https://ClinicalTrials.gov/show/NCT00003120 |
Completed |
Southwest Oncology Group |
2003-06-30 |
| NCT00021034 |
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00021034 |
Completed |
Memorial Sloan Kettering Cancer Center |
2001-08-31 |
| NCT00003334 |
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract |
https://ClinicalTrials.gov/show/NCT00003334 |
Completed |
NYU Langone Health |
2001-12-31 |
| NCT00006454 |
Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer |
https://ClinicalTrials.gov/show/NCT00006454 |
Completed |
AGO Study Group |
2006-08-31 |
| NCT00022347 |
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00022347 |
Completed |
National Cancer Institute (NCI) |
2004-04-30 |
| NCT00075712 |
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00075712 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00074867 |
Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00074867 |
Completed |
Pfizer |
NA |
| NCT00017017 |
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00017017 |
Completed |
National Cancer Institute (NCI) |
2003-02-28 |
| NCT00012090 |
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum |
https://ClinicalTrials.gov/show/NCT00012090 |
Completed |
Memorial Sloan Kettering Cancer Center |
2004-04-30 |
| NCT00072267 |
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00072267 |
Completed |
University Health Network, Toronto |
2005-04-30 |
| NCT00004074 |
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
https://ClinicalTrials.gov/show/NCT00004074 |
Completed |
National Cancer Institute (NCI) |
2009-02-28 |
| NCT00066729 |
Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00066729 |
Completed |
National Cancer Institute (NCI) |
2006-07-31 |
| NCT00066651 |
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT00066651 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00066456 |
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00066456 |
Completed |
Gynecologic Oncology Group |
2010-07-31 |
| NCT00031954 |
Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00031954 |
Completed |
AGO Study Group |
2004-04-30 |
| NCT00063401 |
Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00063401 |
Completed |
Eli Lilly and Company |
2006-06-30 |
| NCT00030446 |
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00030446 |
Completed |
Canadian Cancer Trials Group |
2005-02-11 |
| NCT00061308 |
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00061308 |
Completed |
GlaxoSmithKline |
2004-09-30 |
| NCT00060359 |
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00060359 |
Completed |
Gynecologic Oncology Group |
2009-01-31 |
| NCT00059787 |
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma |
https://ClinicalTrials.gov/show/NCT00059787 |
Completed |
National Cancer Institute (NCI) |
2010-05-31 |
| NCT00059618 |
PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00059618 |
Completed |
M.D. Anderson Cancer Center |
2007-04-30 |
| NCT00058435 |
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00058435 |
Completed |
Memorial Sloan Kettering Cancer Center |
2004-03-31 |
| NCT00055614 |
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00055614 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00052468 |
Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00052468 |
Completed |
AGO Study Group |
2009-07-31 |
| NCT00049556 |
Gefitinib in Treating Patients With Cervical Cancer |
https://ClinicalTrials.gov/show/NCT00049556 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00045175 |
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00045175 |
Completed |
University Health Network, Toronto |
2013-06-30 |
| NCT00041080 |
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00041080 |
Completed |
National Cancer Institute (NCI) |
2011-01-31 |
| NCT00039585 |
Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor |
https://ClinicalTrials.gov/show/NCT00039585 |
Completed |
National Cancer Institute (NCI) |
2006-02-28 |
| NCT00033605 |
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis |
https://ClinicalTrials.gov/show/NCT00033605 |
Completed |
Alliance for Clinical Trials in Oncology |
2006-07-31 |
| NCT00032162 |
Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer |
https://ClinicalTrials.gov/show/NCT00032162 |
Completed |
AGO Study Group |
2005-05-31 |
| NCT00028912 |
Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00028912 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00028743 |
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00028743 |
Completed |
Canadian Cancer Trials Group |
2008-03-05 |
| NCT00019461 |
Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00019461 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00008138 |
S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00008138 |
Completed |
Southwest Oncology Group |
2009-09-30 |
| NCT00006981 |
Immunotoxin Therapy in Treating Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT00006981 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00006942 |
Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00006942 |
Completed |
National Cancer Institute (NCI) |
2004-03-31 |
| NCT00006391 |
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00006391 |
Completed |
NYU Langone Health |
2004-11-30 |
| NCT00004934 |
Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00004934 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00003896 |
S9912 Combination Chemo in Stage III Ovarian Cancer, |
https://ClinicalTrials.gov/show/NCT00003896 |
Completed |
Southwest Oncology Group |
2008-02-29 |
| NCT00003636 |
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00003636 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2009-01-31 |
| NCT00003385 |
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer |
https://ClinicalTrials.gov/show/NCT00003385 |
Completed |
Gynecologic Oncology Group |
2007-01-31 |
| NCT00002895 |
Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00002895 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00006155 |
SU5416 and Carboplatin to Treat Ovarian Cancer |
https://ClinicalTrials.gov/show/NCT00006155 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00035100 |
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer |
https://ClinicalTrials.gov/show/NCT00035100 |
Completed |
Novartis |
2003-06-30 |
| NCT00126542 |
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer |
https://ClinicalTrials.gov/show/NCT00126542 |
Completed |
National Cancer Institute (NCI) |
2007-01-31 |